Welcome to Markets Desk, here's what's moving the needle right now.
Karyopharm Therapeutics is pushing for accelerated approval of its drug selinexor in combination with ruxolitinib for myelofibrosis patients. The company has submitted a supplemental new drug application to the FDA and is requesting priority review, which if granted would compress the agency's standard review timeline considerably — a meaningful catalyst for a small-cap biotech watching every regulatory step closely.
Shifting to infrastructure, SpaceX is moving to manufacture its own gas turbine components in-house, with Elon Musk saying the decision could bring natural gas power capacity online up to eighteen months faster than waiting on outside suppliers. The move underscores just how acute the energy bottleneck has become for AI-driven operations, and it signals that the largest tech players are no longer willing to depend on traditional supply chains to meet surging power demand.
Meanwhile, an MIT economist is urging a reframe of the conversation around America's forty trillion dollars in federal debt, arguing that sustainability is the wrong lens entirely. The more pressing concern, the expert says, is the economic drag that rising debt service burdens place on growth, investment, and fiscal flexibility — a distinction that matters enormously for bond markets and long-term rate expectations.
That's the tape. Markets Desk, signing off the floor.
